Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. [electronic resource]
Producer: 20090820Description: 3659-63 p. digitalISSN:- 1527-7755
- Benzamides
- Cause of Death
- Cohort Studies
- Cytogenetics
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Female
- Follow-Up Studies
- Fusion Proteins, bcr-abl -- genetics
- Humans
- Imatinib Mesylate
- Incidence
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
- Neoplasm, Residual -- drug therapy
- Philadelphia Chromosome
- Piperazines -- administration & dosage
- Polymerase Chain Reaction
- Probability
- Protein Kinase Inhibitors -- administration & dosage
- Pyrimidines -- administration & dosage
- Sensitivity and Specificity
- Severity of Illness Index
- Survival Analysis
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.